导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.41% | 2066/4773 |
| 近一周 | -1.36% | 2068/5465 |
| 近一月 | -2.79% | 1907/5421 |
| 近一季 | -5.54% | 2106/5231 |
| 近半年 | -0.82% | 1595/4920 |
| 近一年 | 4.25% | 1890/4394 |
| 近两年 | 52.84% | 1424/2954 |
| 近三年 | 34.14% | 937/2253 |
| 成立以来 | 96.81% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.88% 2947/4961 |
13.27% 2035/5312 |
- - |
- - |
| 2025 | 21.09% 2057/4813 |
-0.59% 2316/3635 |
1.95% 1995/4076 |
18.64% 2266/4524 |
0.71% 1827/4813 |
| 2024 | 16.31% 825/3463 |
2.61% 745/2808 |
-1.24% 997/3014 |
16.03% 1559/3129 |
-1.07% 1576/3463 |
| 2023 | -9.28% 1144/2656 |
3.77% 1131/2280 |
-4.75% 1277/2385 |
-2.63% 703/2515 |
-5.74% 1484/2655 |
| 2022 | -18.34% 693/2207 |
-14.00% 890/1919 |
7.20% 513/2016 |
-12.51% 716/2113 |
1.24% 1330/2208 |
| 2021 | 3.75% 602/1822 |
-3.14% 768/1255 |
8.54% 613/1330 |
-3.23% 620/1466 |
1.97% 734/1822 |
| 2020 | 43.56% 240/1250 |
-6.50% 489/1028 |
16.19% 451/1067 |
15.88% 188/1164 |
14.04% 305/1184 |
| 2019 | 37.85% 326/1092 |
25.66% 452/739 |
-0.35% 247/788 |
2.49% 296/850 |
7.41% 438/918 |
| 2018 | - - |
- - |
- - |
0.82% 144/660 |
-11.02% 241/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 南方MSCI中国A股联接A VS. 长安沪深300非周期A(740101) |